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Abstract
BACKGROUND: Metronomic chemotherapy involves frequent, regular administration of cytotoxic drugs at non-
toxic doses, usually without prolonged breaks. We investigated the therapeutic efficacies of metronomic S-1,
an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and vascular endothelial
growth factor (VEGF) receptor tyrosine kinase inhibitor, in models of hepatocellular carcinoma (HCC). METHODS:
Wecompared anti-HCC effects and toxicity in the six treatment groups: control (untreated), maximum tolerated dose
(MTD) S-1, metronomic S-1, vandetanib, MTD S-1 with vandetanib, and metronomic S-1 with vandetanib. Tumor
microvessel density (MVD) and tumor apoptosis were evaluated by immunohistochemistry. The expression of VEGF
and thrombospondin-1, an endogenous inhibitor of angiogenesis, was analyzed by Western blot. RESULTS:Metro-
nomic S-1 significantly inhibited tumor growth, which was enhanced by combination with vandetanib. With respect
to toxicities, MTD S-1 caused severe body weight loss and myelosuppression, whereas metronomic S-1 did not
cause any overt toxicities. Moreover, metronomic S-1 or metronomic S-1 with vandetanib prolonged survival, the
latter treatment providing the greatest benefit. Metronomic S-1 and metronomic S-1 with vandetanib decreased
MVDs and increased apoptosis in tumor tissues. The expression of VEGF in tumor tissues was upregulated by van-
detanib and metronomic S-1 with vandetanib, whereas the expression of thrombospondin-1 was upregulated by
metronomic S-1 andmetronomic S-1 with vandetanib. CONCLUSION:Metronomic S-1 with an antiangiogenic agent
seems to be an effective and safe therapeutic strategy for HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common solid tu-
mor and the third leading cause of cancer-related deaths globally [1].
Although prognosis of early and intermediate stage HCC has im-
proved owing to advances in treatments, there are few proven effective
systemic therapies for advanced HCC [2]. In particular, conventional
chemotherapy using cytotoxic drugs for advanced HCC has not been
shown to improve survival. Almost all cases of HCC occur in patients
with chronic liver disorders, such as liver cirrhosis. Patients with liver cir-
rhosis have liver dysfunction and also pancytopenia. These pathologies
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limit the use of conventional chemotherapy as a treatment strategy
for HCC.
Conventional chemotherapy often involves pulsatile administration
schedules using maximum tolerated doses (MTDs) of cytotoxic drugs.
The long break periods between therapies not only allow recovery from
various toxicities, especially myelosuppression, but also provide an oppor-
tunity, unfortunately, for the drug-treated tumors to recover as well [3]. In
contrast, metronomic chemotherapy is given at frequent intervals using
minimally or nontoxic doses without prolonged breaks. In several pre-
clinical studies, such metronomic protocols have shown surprisingly
effective antitumor effects, despite the reduced toxicity [4–6].
S-1 is an orally novel cytotoxic 5-flurouracil (5-FU) prodrug,which consists
of tegafur and two biochemical modulators, 5-chloro-2,4-dihydroxypyridine
and potassium oxonate [7]. 5-Chloro-2,4-dihydroxypyridine competi-
tively inhibits dihydropyrimidine dehydrogenase approximately 180 times
more effectively than uracil. Thus, S-1 gives rise to high concentrations
of 5-FU in blood and tumor tissue for long-term periods since bio-
chemical modulation [7,8]. A drug similar to S-1, namely, UFT, has
been used successfully in metronomic preclinical studies [5]. Moreover,
in the clinic it has been used successfully in randomized phase 3 trials in
a metronomic fashion to treat in an adjuvant manner a variety of early
stage cancers, after surgery, including non–small cell lung cancer [9]
and breast cancer [10]. Because S-1 is thought to be more potent than
UFTwith respect to the effect of biochemical modulations, one might
expect a stronger antitumor effect by using S-1 [7]. In this study, we
describe a method of administering metronomic S-1 to treat HCC
and compare it to conventional MTD S-1 chemotherapy, either alone
or with an antiangiogenic drug.
Tyrosine kinase inhibitors such as sorafenib have proven activity in
HCC patients and now represent one of the few effective systemic
therapies for HCC [11]. Preclinical studies have also shown that the
antitumor effect of metronomic chemotherapy can be significantly
enhanced by combination with vascular endothelial growth factor
(VEGF) pathway targeting agents [12,13]. In this study, we show here
that metronomic S-1 might be a promising therapy to consider for
concurrent daily combination with an oral antiangiogenic drug, in this
case, vandetanib (ZD6474; AstraZeneca Pharmaceuticals, Macclesfield,
UK). Vandetanib inhibits not only the catalytic function of VEGFR-2
but also EGF receptors (EGFRs), in contrast to sorafenib or sunitinib
that do not affect EGFRs [14]. We evaluated the efficacies of vandeta-
nib alone in vivo for HCC-bearing mice using various hepatoma cell
lines that had different expressions of EGFR (submitted for publi-
cation). EGFR is known to contribute to 5-FU drug resistance, and
5-FU is the major metabolite of S-1 [15]. Therefore, there is a rationale
for drug targeting of both EGF receptors and VEGF receptors along
with metronomic chemotherapy, which was the purpose of this study.
Thus, we investigated the efficacy of combining with each treatment
schedule of S-1 and vandetanib using twoHCC cell lines, which express
low or high levels of EGFR, that is, KYN-2 and Huh-7, respectively.
Overall, our results suggest that the combination treatment of metro-
nomic S-1 plus vandetanib may be useful for the therapy of HCC.
Materials and Methods
Cell Lines and Culture
In human hepatoma cell lines, Huh-7 was originally purchased from
CAMBREX Bio Science Walkersville, Inc (Walkersville, MD), and
KYN-2was provided by theDepartment of Pathology, KurumeUniver-
sity School of Medicine. Cells were maintained in Dulbecco modified
Eagle medium (DMEM; Gibco Invitrogen Cell Culture Co, Auckland,
New Zealand) supplemented with 10% fetal bovine serum (FBS).
Human umbilical vascular endothelial cells (HUVECs) were pur-
chased from CAMBREX Bio ScienceWalkersville, Inc, and maintained
with endothelial cell growth medium-2 (Clonetics, San Diego, CA)
containing 5% FBS.
Animals and Drugs
Male 5-week-old nude mice (BALB/c nu/nu) were purchased from
Kyudo KK (Fukuoka, Japan). All experiments were conducted in
accordance with the National Institutes of Health guidelines for the
Care and Use of Laboratory Animals.
5-FU was purchased from Kyowa Hakko Kogyo Co, Ltd (Tokyo,
Japan). S-1 was provided by Taiho Pharmaceutical Co, Ltd (Tokyo,
Japan). S-1 consists of a mixture of tegafur, gimeracil, and oteracil at
molar ratio of 1:0.4:1 in 0.5% hydroxypropylmethylcellulose
(HPMC) solutions. Vandetanib (ZD6474; Zactima) was provided
by AstraZeneca Pharmaceuticals (Macclesfield, UK).
In Vitro Cell Proliferation Assay
As the tegafur component of S-1 is physiologically converted to 5-
FU in the body, we evaluated the difference of antiproliferative effects
in vitro of 5-FU using different schedules with both hepatoma cells
and HUVECs. Approximately 1000 cells in 100 μl of DMEM con-
taining 10% FBS was added to each well of 96-well plate. After incuba-
tion for 24 hours, the medium was exchanged to the serum-containing
mediumwith various concentrations of 5-FU (0, 1, 10, 100, 500, 1000,
10,000 ng/ml). Each cell line was exposed to 5-FU for 5 days. To eval-
uate the antiproliferative effect of “MTD” versus “metronomic” chemo-
therapy, exchange of themedium containing 5-FUwas performed using
different schedules. For themetronomic schedule, themedium contain-
ing 5-FU was exchanged daily as described previously [16]. For the
MTD schedule, the medium containing 5-FU was not changed. After
incubation, cell proliferation was evaluated by a tetrazolium-based assay
(Cell Count Reagent SF; Nakalai Tesque, Inc, Kyoto, Japan).
Determination of the Optimal Dose for S-1 Using
Metronomic Chemotherapy
We determined the optimal metronomic dose of S-1 according to a
previous report, which involved evaluating different doses of a chemo-
therapy drug both for antitumor effects and toxicity, with the aim of
determining a dose that has minimal toxicity but retains good efficacy
[17]. A total of 5 × 106 Huh-7 cells were injected into the flank re-
gions of nude mice. Therapy with different doses of S-1 was initiated
when the estimated tumor volume (0.52 × length × width2) reached
150 to 200 mm3. Mice received S-1 orally administrated by gavage
with the following agents on a daily basis for 14 days: 1) HPMC as
the control group; 2) S-1, 7.5 mg/kg per day; 3) S-1, 5.0 mg/kg per
day; 4) S-1, 2.5 mg/kg per day; or 5) S-1, 1.0 mg/kg per day. Tumor-
bearing mice were randomly divided into groups of 10 mice. The
mice were killed at day 15 after start of treatment. The inhibition rate
of tumor growth (IR %) was calculated as follows: IR % = (1 − mean
RTVof treatment group / mean RTVof control group) × 100, where
RTV indicates the relative tumor volume: tumor volume on killing /
tumor volume on initial treatment. For comparison of the toxicity in
each group, mouse body weights were measured every 3 days. Periph-
eral leukocyte count and hemoglobin (Hb) concentrations of these
mice were also measured at day 15.
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Tumor Growth and Toxicity Assessment in the Subcutaneous
Tumor Transplant Model
We selected as the optimal metronomic dosage for S-1, 5.0 mg/kg
per day based on our aforementioned study. We selected the MTD for
S-1 15 mg/kg per day for 7 days, followed by a 7-day break period,
based on previous published findings [6]. To compare the antitumor
effect and toxicity caused by MTD or metronomic S-1, long-term
experiments were performed using the Huh-7 subcutaneous trans-
plant model. Mice were randomly divided to six groups: 1) HPMC
as the control group; 2) MTD S-1, 15 mg/kg per day p.o. for 1 week,
followed by a 1-week break period for a cumulative dose of 95 mg/kg;
3) metronomic S-1, 5 mg/kg per day p.o. for 2 weeks without any break
period for a cumulative dose of 70 mg/kg; 4) vandetanib 25 mg/kg per
day p.o. for 2 weeks; 5) MTD S-1 with vandetanib; or 6) metronomic
S-1 with vandetanib. Each group consisted of 10 mice. It is important
to note that the cumulative metronomic doses were distinctly less than
the cumulative MTD. In other words, whereas the schedule used was
“dose-dense,” it was not “dose intense.” The aforementioned schedules
were performed in two cycles, 4 weeks in total. Estimated tumor vol-
umes were measured every 3 days, and all mice were killed after 4 weeks
of treatment. For comparison of the toxicity in each group, mouse body
weights were measured every 3 days. Peripheral leukocyte count and
hemoglobin (Hb) concentrations in these mice were also measured
at sacrifice.
Tumor Growth and Survival Assessment in the Orthotopic
Transplant Model
We also examined tumor growth using an orthotopic liver trans-
plant model. The mice were implanted with 2 × 106 KYN-2 cells into
the left lobe liver. Mice were randomly divided into six groups, as out-
lined above, and therapy was initiated 7 days after implantation of
tumor cells. Each group consisted of 10 mice. The mice were killed
at day 29 of initial treatment, and tumor volumes were evaluated.
In addition, a survival study was also performed using the KYN-2
orthotopic transplant model for the six groups as mentioned above.
Each group consisted of 10 mice. In the group for survival observa-
tion, animals were killed according to (pre)clinical signs of weakness,
for example, anorexia, or greater than 20% weight loss, and days of
life were recorded from initial treatment.
Immunohistochemical Staining of CD31, PCNA, and TUNEL
The sections of all tumor tissues obtained from KYN-2 orthotopic
transplant model were boiled for 30 minutes by high pH target re-
trieval solution (DAKO Japan, Kyoto, Japan) for antigen retrieval. The
sections were incubatedwith rabbit anti–humanCD31 antibody (diluted
1:300; Abcam, Inc, Tokyo, Japan) and rabbit anti–human PCNA anti-
body (diluted 1:250; Abcam, Inc) at 4°C overnight. Then the avidin-
biotin procedures were subsequently performed using a Vectastatin
ABC Kit (Vector Laboratories, Inc, Burlingame, CA). The sections were
reacted with 0.005% H2O2–3,3′-diaminobenzidine at room tempera-
ture for 1 minute. For quantification of microvessel density (MVD),
CD31-positive vessels were counted in randomly selected 30 areas per five
tumors in each treatment group at 200-fold magnification.
The terminal deoxynucleotidyl transferase–mediated dUTP nick
end labeling (TUNEL) method was performed for the evaluation
of apoptosis in each of the treated tumor tissues. TUNEL labeling
was performed using the ApopTag Kit (Chemicon, Temecula, CA)
according to the manufacturer’s instructions. The stained sections
of tumors of each group were reviewed, and the apoptosis index,
determined by TUNEL staining, was determined by counting at
least 1000 cells in five randomly selected high-power fields (magni-
fication, ×200).
Expression of Thrombospondin-1 and VEGF in Tumor Tissues
We examined the expression of VEGF and thrombospondin-1
(TSP-1) in treated tumor tissues using Western blot analysis. TSP-
1 is a known endogenous antiangiogenic protein [18]. Five samples
of each treatment group and control group were loaded in equal con-
ditions, respectively. Thirty micrograms of protein was loaded onto a
NuPAGE 4% to 12% Bis-Tris gel (Invitrogen, CA). Membranes
were incubated with rabbit anti–TSP-1 antibody (1:350 dilution;
Abcam, Inc) or rabbit anti-VEGF antibody (1:500 dilution; Abcam,
Inc) at 4°C overnight. Equal protein loading was assessed by mouse
anti–β-actin antibody (1:1000 dilution; Sigma, St Louis, MO). After
incubation with HRP-conjugated anti–rabbit immunoglobulin G
(1:10,000 dilution; GE Healthcare UK Ltd, Buckinghamshire,
UK) or HRP-conjugated anti–mouse immunoglobulin G antibody
(1:5000 dilution; GE Healthcare UK Ltd) for 1 hour, immunoreac-
tive bands were stained by an enhanced chemiluminescence Western
blot analysis system using LAS 4000 mini (Fujifilm, Tokyo, Japan)
and were calculated with the amount of luminescence in each sample
using multigauge software (Fujifilm). The relative amount of lumi-
nescence in each treatment group for the control group was expressed
as [(treatment group VEGF or TSP-1 / treatment group β-actin) /
(control group VEGF or TSP-1 / control group β-actin)] and com-
pared with each group.
Statistical Analysis
All experimental data were expressed as mean ± SD. Differences
between groups were examined for statistical significance using the
Mann-Whitney U test, the Kruskal-Wallis test, and nonparametric
analysis of variance. If the one-way analysis of variance was signifi-
cant, differences between individual groups were estimated using the
Fisher least significant difference test. Overall survival was estimated
according to the Kaplan-Meier method and compared using the log-
rank test. P < .05 was considered to be statistically significant.
Results
Comparison of Antiproliferative Effects of Metronomic versus
MTD Type Chemotherapy In Vitro
The 50% inhibitory concentration (IC50) levels of metronomic
and MTD schedules of 5-FU, the major metabolite of S-1, for each
cell line are shown in Table 1. The antiproliferative effects of 5-FU
for each cell line were found to be dose-dependent (Figure 1, A–C ).
The IC50 levels for the MTD and metronomic schedule for Huh-7
cells were 3.84 and 0.77 μM, respectively (Figure 1A). The IC50
Table 1. IC50 Levels ofMTDandMetronomic Schedule inHepatomaCell Lines and Endothelial Cell.
5-FU IC50 (μM)
MTD Metronomic
Hepatoma cell lines
Huh-7 3.84 0.77
KYN-2 7.69 3.84
Endothelial cell
HUVECs 7.7 0.76
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levels for KYN-2 were 7.69 and 3.84 μM, respectively. For the hep-
atoma cell lines, the metronomic schedule inhibited cell proliferation
at approximately 1/2 to 1/4 concentrations of 5-FU compared with
MTD schedule (Table 1). The metronomic schedule for HUVECs
inhibited cell proliferation at apparently lower levels (IC50 levels,
0.76 μM) approximately 1/10 the concentration of 5-FU compared
with MTD schedule (IC50 levels, 7.7 μM; Table 1).
Determination of the Optimal Dose of S-1 for Metronomic
Chemotherapy In Vivo: Maximum Tumor Growth Inhibition
with Minimal Toxicity
In the 7.5- and 5.0-mg/kg-per-day S-1 treatment groups, there
were significant differences in suppression of tumor growth com-
pared with the control group (P < .05; Figure 2A), and dosages lower
than 2.5 mg/kg per day S-1 were not statistically effective compared
with the control group. In addition, we evaluated body weight loss
and myelosuppression toxicities associated with administration of
S-1 (Figure 2, B–D). With respect to body weight loss, there was no
significant difference between each group (Figure 2B). But only the
7.5-mg/kg-per-day group showed severe toxicity as determined by reduc-
tions inHb concentration and leukocyte count (P < .001, comparedwith
the control group; Figure 2,C andD). Therefore, we selected 5.0 mg/kg
per day as the optimal metronomic dosage of S-1, which was used in all
subsequent experiments.
Evaluation of the Antitumor Effect and Toxicity for
Metronomic S-1 Chemotherapy in the Subcutaneous
Transplant Tumor Model
In the assay for tumor growth, statistical differences were observed
between the control group and all treatment groups (Figure 3A).
Figure 1. Inhibitory effect of metronomic chemotherapy for each cell line tested in a cell proliferation assay. To evaluate the antiprolifera-
tive effect of “MTD” and “metronomic” chemotherapy in vitro, exchange of the medium containing 5-FU was performed in different
schedules. For the metronomic schedule, the medium containing 5-FU (0, 1, 10, 100, 500, 1000, and 10,000 ng/ml) was exchanged once
a day. For the MTD schedule, the medium containing 5-FU was not changed. Data are shown as a ratio of the control and expressed as
mean ± SD of 10 samples. *P < .001 compared with each schedule. Dark gray–shaded columns show MTD schedule, and light gray–
shaded columns showed metronomic schedule. (A) HUVEC. HUVEC was cultured with 100 μl of endothelial cell growth medium-2 with
5% FBS containing 5-FU. (B) Huh-7. (C) KYN-2. Hepatoma cells were cultured with 100 μl of DMEM with 10% FBS containing 5-FU.
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Metronomic S-1 potently inhibited tumor growth compared with
MTD S-1 (P < .01). The mean tumor volumes were 4810.5 ±
1440.9 cm3 in the control group, 3212.6 ± 1364.7 cm3 in the
MTD S-1 group, 1927.1 ± 652.9 cm3 in the metronomic S-1 group,
and 2331.4 ± 662.1 cm3 in the vandetanib group, respectively. The
mean tumor volumes in the MTD S-1 plus vandetanib group and
metronomic S-1 plus vandetanib group were 2026.7 ± 1106.7 and
1383.7 ± 697.5 cm3, respectively. The greatest inhibition of tumor
growth was induced by the metronomic S-1 in combination with
vandetanib (Figure 3A). In addition, we evaluated toxicity in each
of Huh-7 subcutaneous tumor treatment groups (Figure 3, B–D).
In leukocyte count, there were no significant differences in the
groups (Figure 3B). In Hb concentration, the control group was
12.84 ± 1.82 g/dl, the MTD S-1 group was 9.77 ± 3.63 g/dl, the
metronomic S-1 group was 11.73 ± 3.27 g/dl, and the vandetanib
group was 12.34 ± 2.77 g/dl. For the combination treatments, the
MTD S-1 plus vandetanib group was 8.24 ± 1.64 g/dl, and for
the metronomic S-1 plus vandetanib group, it was 11.74 ± 1.55 g/dl
(Figure 3C). With respect to rate of body weight loss, in the MTD S-1
monotherapy and MTD S-1 with vandetanib groups, the values ob-
served were 10.48% ± 6.85% and 8.59% ± 5.02% reduction compared
with the control group, respectively. Vandetanib, metronomic S-1, and
the combination therapy resulted in 5.64% ± 4.23%, 3.04% ± 2.23%,
and −0.51% ± 5.56% reduction compared with the control group,
respectively (Figure 3D). Both the MTD S-1 and MTD S-1 plus van-
detanib treatment groups experienced severe body weight loss and re-
duced Hb concentrations compared with the control group (Figure 3,
C and D). In marked contrast, the metronomic S-1 monotherapy and
metronomic S-1 with vandetanib groups did not manifest any overt
toxicity (Figure 3, B–D).
Evaluation of Antitumor Efficacy Using Metronomic S-1
Chemotherapy in an Orthotopic Liver Transplant Model
For tumor volume assessments, all treatments except MTD S-1
monotherapy were effective compared with the control group
(Figure 4A). Tumor volumes at sacrifice were 4186.0 ± 1128.0 cm3
in the control group, 3259.0 ± 788.7 cm3 in the MTD S-1 group,
1501.3 ± 1002.2 cm3 in the metronomic S-1 group, and 1582.0 ±
354.9 cm3 in the vandetanib group. There was a significant differ-
ence between metronomic S-1 and MTD S-1 in tumor growth inhi-
bition (P < .05; Figure 4A). For the combination treatment groups,
tumor volumes were 931.1 ± 331.7 cm3 in the MTD S-1 plus van-
detanib group and 875.0 ± 369.4 cm3 in the metronomic S-1 plus
vandetanib group. There was no significant difference between the
metronomic S-1 plus vandetanib group and the MTD S-1 plus van-
detanib group. However, the greatest inhibition of tumor growth was
detected in the metronomic S-1 plus vandetanib treatment group (P <
.001; Figure 4A).
Figure 2. Determination of the optimal dose of S-1 in metronomic chemotherapy. Huh-7 subcutaneous tumor models were treated daily
with either HPMC or different metronomic doses of S-1 (1.0, 2.5, 5.0, or 7.5 mg/kg per day) for 14 consecutive days. (A) Inhibition rates of
tumor volumes (%) are expressed as mean ± SD (n = 10 per group). Dosages of 5.0 and 7.5 mg/kg per day S-1 groups statistically
inhibited tumor growth compared with the control group (*P < .05). (B–D) Toxicity parameters are represented as mean ± SD. (B) Body
weight (BW) changes on killing were calculated according to the following formula: BW change (%) = [(BW on sacrifice)− (BW on day 0)] ×
100. (C) Hb concentration. (D) Leukocyte count. Each different dose of S-1 did not show body weight loss. However, the only 7.5-mg/kg-per-
day S-1 group represented severe myelosuppression, such as decreased Hb concentration or leukocyte count. †P< .001 by compared with
the control group.
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Evaluation of Survival Using Metronomic S-1 Chemotherapy
in an Orthotopic Liver Transplant Model
The mean survival time in the control group was 28.9 ± 6.4 days.
MTDS-1 did not prolong survival (mean survival time, 29.6 ± 3.9 days).
In contrast, metronomic S-1 significantly prolonged survival (mean sur-
vival time, 34.3 ± 4.8 days). The mean survival time in the vandetanib
group was 33.6 ± 5.0 days. MTD S-1 plus vandetanib treatment did
not prolong survival times compared with vandetanib monotherapy
(mean survival time, 37.6 ± 5.5 days). However, the metronomic S-1
plus vandetanib group provided the greatest prolonged survival times
among all the treatment groups (mean survival time, 49.6 ± 11.5 days;
Figure 4B).
Effect of Metronomic S-1 Chemotherapy Alone and in
Combination with Vandetanib on Parameters of
Tumor Angiogenesis
The results in Figure 5 show the MVD count in each treatment
group. There was no significant difference in the MVD count be-
tween the control and the MTD S-1 group (control 41.1 ± 9.2,
MTD S-1 35.8 ± 5.5; Figure 5B). However, tumor MVD was de-
creased in the metronomic S-1 group (17.2 ± 4.1) compared with the
control group (P < .001) and the MTD S-1 group (P < .001;
Figure 5B). Tumor MVD in mice treated with vandetanib was
13.7 ± 5.1. In the MTD S-1 plus vandetanib group, the MVD count
was 18.8 ± 7.4. Metronomic S-1 plus vandetanib group showed the
greatest reduction of tumor MVD (P < .01 compared with MTD S-1
plus vandetanib group, 8.2 ± 1.6; Figure 5B).
Detection of Proliferation and Apoptotic Cells in
Tumor Tissues
To further investigate the mechanism of the observed antitumor
effect, we examined the effect of metronomic S-1 and in combina-
tion with vandetanib on tumor cell proliferation and apoptosis (Fig-
ure 5). With respect to tumor cell proliferation, there were no
differences between the control and all treated groups. The mean
Figure 3. Therapeutic effects of metronomic S-1 chemotherapy in the Huh-7 subcutaneous tumor transplant model. (A) Tumor-bearing
nude mice (n = 10 per group) were treated in the following six groups: 1) HPMC as the control group (blue); 2) MTD S-1 15 mg/kg per
day for 1 week, followed by a 1-week break period (purple); 3) metronomic S-1 5 mg/kg per day for 2 weeks without break period (green);
4) vandetanib 25 mg/kg per day for 2 weeks (red); 5) MTD S-1 with vandetanib (yellow); or 6) metronomic S-1 with vandetanib (black). All
treatments were performed for 4 weeks in total. Tumor volume changes are expressed as mean ± SD. All treatments showed efficacy
compared with the control group (*P < .05), and the metronomic S-1 therapy was more effective than the MTD S-1 treatment. The
metronomic S-1 with vandetanib significantly inhibited tumor growth compared with the control group (†P< .001). (B–D) Toxicity param-
eters are expressed as mean ± SD. (B) Hb concentration. (C) Leukocyte count. (D) Rate of body weight loss. MTD S-1 and the MTD S-1
with vandetanib showed severe body weight loss (*P < .01) and decreased Hb concentration (†P < .05) compared with the control
group. Metronomic S-1 and the metronomic S-1 with vandetanib did not show any overt toxicities.
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number of apoptotic tumor cells (apoptotic index) measured in the
control group was 6.2 ± 2.6. The MTD S-1 group did not show any
significant difference (6.1 ± 4.9). However, the metronomic S-1 and
vandetanib groups showed a significant increase in the apoptosis index
(26.0 ± 5.4 and 18.4 ± 8.8, respectively, P < .0001). A significant
increase in the tumor cell apoptosis index was also observed in the
metronomic S-1 plus vandetanib group with 42 ± 3.5 (P < .0001).
Expression of VEGF and TSP-1 in Tumor Tissues
The results in Figure 6 show the expression of TSP-1 and VEGF
in treated tumor tissues. The expression level of TSP-1 was signifi-
cantly upregulated by approximately two- to three-fold in both the
metronomic S-1 and the metronomic S-1 plus vandetanib treatment
groups (P < .05 compared with the control group; Figure 6, A and
B). With respect to expression levels of VEGF, there were no differ-
ences between the control and the MTD S-1 and metronomic S-1
groups (Figure 6, C and D). In contrast, the vandetanib and the met-
ronomic S-1 plus vandetanib groups showed significantly upregu-
lated the VEGF expression compared with the control group (P <
.05; Figure 6, C and D). There was a significant difference between
the vandetanib monotherapy group and the metronomic S-1 plus
vandetanib treatment group (P = .045).
Discussion
Our results add to an expanding body of literature reporting the thera-
peutic benefit of metronomic chemotherapy, especially when it is com-
bined concurrently with a targeted antiangiogenic drug [5,12,13].
Moreover, to our knowledge, this is the first preclinical report of using
S-1 in a metronomic dosing and administration schedule for HCC pre-
clinical model. Also noteworthy is that we undertook a comparative
Figure 4. Assessment of therapeutic effects in KYN-2 liver transplant model. Tumor-bearing nude mice were treated in the following six
groups: 1) HPMC as the control group (blue); 2) MTD S-1: 15 mg/kg per day for 1 week, followed by 1 week break period (purple); 3)
metronomic S-1: 5 mg/kg per day for 2 weeks without break period (green); 4) vandetanib 25 mg/kg per day for 2 weeks (red); 5) MTD S-1
with vandetanib (yellow); or 6) metronomic S-1 with vandetanib (black). (A) Inhibition of tumor growth for KYN-2 liver transplant model. All
treatments were performed 4 weeks in total. There was no significant difference between the control and the MTD S-1 groups. The
metronomic S-1 group contributed to obvious inhibitory effect of tumor growth (*P < .05 compared with the control and the MTD S-1
groups). The metronomic S-1 with vandetanib treatment group showed the greatest inhibitory effect of tumor growth among all the
groups (†P < .001). (B) Survival of mice treated with MTD S-1 or metronomic S-1 and in combination with vandetanib (n = 10 per group).
Treatment was continued until mice were moribund, and days of life were recorded. Survival data were compared for significance with
the log-rank test. MTD S-1 did not prolong survival compared with the control group. In contrast, metronomic S-1 prolonged survival
compared with the control and MTD S-1 groups. The metronomic S-1 with vandetanib group provided the most effective therapy with
longest survival times among all the groups (P < .001).
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analysis of the effects of S-1 given in a more conventional MTD sched-
ule with metronomic S-1, and our results consistently showed the met-
ronomic dosing/schedule was superior to the MTD protocol, both in
terms of increased antitumor efficacy and reduced toxicity. Importantly,
in this regard, the metronomic protocol we used involved a cumulative
dose over time that was 30% less than the corresponding MTD proto-
col. Below we discuss a number of different aspects of our results and
some of the translational/clinical implications.
Antiangiogenic Effects Mediated by Metronomic
S-1 Chemotherapy
Previous studies during the last decade have indicated that metro-
nomic chemotherapy regimens using cytotoxic agents inhibit tumor
growth by various mechanisms, namely, antiangiogenic effects, direct
tumor cell targeting effects, or anticancer immune responses [4,19,
20]. Our results with metronomic S-1 would seem to confirm the anti-
angiogenic effect findings. First, we found that exposure of 5-FU in
a metronomic-type protocol in vitro brought about a greater antipro-
liferative effect at distinctly low concentrations not only of 5-FU on two
different tumor cell lines but also, especially, HUVECs, compared with
an MTD-like exposure. This is similar to the results of other studies
such as that of Bocci et al. [16] using paclitaxel or the active metabolite
of cyclophosphamide. Second, we found reduced MVD and increased
number of apoptotic tumor cells in mice treated with the metronomic
S-1 schedule but not the MTD protocol. Third, we observed an in-
creased expression of TSP-1, which has been reported previously using
other cytotoxic drugs administered in a metronomic fashion in vivo,
including cyclophosphamide [21]. Fourth, we noted that a tumor cell
line (KYN-2) that is intrinsically resistant in vitro to high concentrations
of 5-FU—themajor metabolite of S-1—nevertheless responds to metro-
nomic S-1 in vivo but not to MTD S-1, suggesting that a target other
than the tumor cell population per se is likely involved in the in vivo
Figure 6. Western blot analysis of TSP-1 and VEGF. The band intensities of both TSP-1 and VEGF in treatment groups were measured
and calibrated with each protein in control group and β-actin. (A and B) The metronomic S-1 and metronomic S-1 with vandetanib groups
showed strongly upregulated the expression of TSP-1 (†P < .001 compared with the control group). (C and D) The expression of tumor
VEGF was increased by the vandetanib and the metronomic S-1 with vandetanib groups. There were no differences between the control
and the MTD S-1, metronomic S-1 group (*P < .05 compared with the control group). There was a significant difference between the
vandetanib and metronomic S-1 with vandetanib group (P = .045).
Figure 5. MVD and apoptosis in tumors tissues. The sections of tumors from the KYN-2 liver transplant model were stained by anti-CD31
antibody and Terminal deoxynucleotidyl transferase (TdT)–mediated dUTP nick-end labeling (TUNEL). Originalmagnification, ×200. The den-
sity ofCD31-positive vessels (arrow) and TUNEL in a tumor field are represented asmean±SD (n=30per group). (A) Representative sections
for each treatment are shown. Bar, 10 μm. (B) There was no significant difference in MVD between the control and the MTD S-1 groups.
Tumor vessel numbers were reduced by metronomic S-1. The metronomic S-1 with vandetanib group showed the most inhibitory effect of
tumor vessel count among all the groups (*P< .001 compared with the control group and the MTD S-1 group). The MTD S-1 group did not
show any significant difference in the number of tumor cell apoptosis index (6.1± 4.9). However, themetronomic S-1 and vandetanib groups
significantly increased in the number of apoptosis index, respectively (26.0 ± 5.4 and 18.4 ± 8.8, P< .0001). A significant increase of tumor
cell apoptosis index was also observed in the metronomic S-1 with vandetanib group with 42 ± 3.5 (P < .0001).
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antitumor activity that was observed using metronomic S-1. Fifth,
O’Reilly et al. [22] have reported that the antiangiogenic effect mediated
by endogenous antiangiogenic factors induces increased apoptosis of
tumor cells, likely a secondary effect due to decreased MVD, whereas
proliferation of tumor cells was not affected. Similarly, tumor apoptotic
cell numbers were increased, whereas proliferation of tumor cells was not
inhibited bymetronomic S-1 chemotherapy in our study.On the basis of
all of the aforementioned data and information, the antitumor effect of
metronomic S-1 chemotherapy was likely to be mainly through anti-
angiogenesis mediated by inhibiting the proliferation of endothelial cells
and inducing the expression of TSP-1, although some additional mecha-
nisms cannot be entirely excluded. The mechanism of antiangiogenesis
of metronomic S-1 chemotherapy is thought to be quite different from
that of vandetanib. Inhibiting VEGFR by vandetanib resulted in
increased VEGF production in tumor tissues, paradoxically, whereas
metronomic S-1 chemotherapy did not increase VEGFproduction. Ebos
et al. [23] reported that this difference of production of VEGFs influ-
enced to achieving malignant potential of cancer cells. Also, at this point,
metronomic chemotherapy is thought to be a promising strategy of
long-term treatment of cancer.
Translational /Clinical Implications of the
Metronomic S-1 + Vandetanib Preclinical Results
There are several potentially important implications of our results
with respect to how they might conceivably be exploited for the future
treatment and management of HCC patients. It is well known that
there are no effective chemotherapy regimens for the treatment of
advanced HCC using conventional chemotherapy regimens. One
reason for this is the frequent underlying liver dysfunction [2]. As a
consequence, using MTD given in conventional schedules is often
contraindicated because of possible excessive toxicity. However, chemo-
therapy drugs given in a metronomic, less toxic fashion may be an alter-
native strategy to circumvent this problem. In this regard, there is
conflicting evidence regarding the clinical benefit of metronomic
UFT, another 5-FU prodrug, at least in the postoperative adjuvant
use for HCC [24]. However, some aspects regarding the negative clin-
ical findings should be taken into consideration. One is the dosing. The
daily dose used in the aforementioned adjuvant study was less than the
dose used for a positive phase 3 adjuvant UFT clinical trial for non–
small cell lung cancer patients [9]. The second is the benefit that might
be gained by using an antiangiogenic drug in combination with metro-
nomic UFT. For example, a recent report by Tang et al. showed that
neither metronomic UFT nor antiangiogenic drug therapy alone had
overt antitumor activity in a model of locally advanced HCC, whereas
these drugs when combined showed significant antitumor activity [25].
Also, in our study, combining with vandetanib resulted in enhanced
antitumor effects for S-1 chemotherapy; nevertheless, MTD S-1 mono-
therapy did not show any effective antitumor effects. VEGFR is related
to chemoresistance for tumor endothelial cells through surviving [26].
Inhibiting VEGFR by vandetanib might have contributed to enhanced
chemosensitivity for tumor endothelial cells. And EGFR is associated
with resistance to 5-FU [15]. Inhibiting EGFR by vandetanib might
have enhanced chemosensitivity to 5-FU. In addition, it is notable in
our study that not only the combination with vandetanib but also met-
ronomic S-1 monotherapy showed significant antitumor effects. Be-
cause S-1 may be superior to UFT in antitumor effect by virtue of
its biochemical modulators [7], S-1 might be an even more suitable
agent for metronomic chemotherapy.
In summary, we have demonstrated preclinically that metronomic
S-1 chemotherapy showed effective therapeutic outcomes without
overt toxicity for treatment of HCC, mainly by suppressing tumor
angiogenesis, and the activity of which is amplified by concurrent
combination with vandetanib. Metronomic S-1 and the concurrent
combination treatment with an antiangiogenic agent might be a
promising treatment strategy for HCC.
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